ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical
company that develops, manufactures, and intends to market specialty
plasma-based biologics for the treatment and prevention of certain
infectious diseases, today announced that its wholly owned subsidiary,
ADMA BioCenters in Norcross, Georgia, received approval from the Korean
Ministry of Food and Drug Safety (MFDS) for the sale of source plasma
into South Korea.
for ADMA Biologics’ Plasma Collection Subsidiary ADMA BioCenters Norcross, GA Facility Expands Global Regulatory Approval Presence investment picks